| [Safety profile of tenofovir amibufenamide therapy extension or switching in patients with chronic hepatitis B: a phase Ⅲ multicenter, randomized controlled trial].Zhonghua Gan Zang Bing Za Zhi | PMID 39528324PMC12898939 | 2024-Oct-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.J Travel Med | PMID 38959854无 PMCID | 2024-Oct-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39419054无 PMCID | 2024-Oct-19 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.RMD Open | PMID 39424404PMC11492937 | 2024-Oct-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med | PMID 39413375PMC11488644 | 2024-Oct-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.N Engl J Med | PMID 39413377PMC7616714 | 2024-Oct-17 | 0.95 | Eligible Phase III randomized trial with primary time-to-event endpoint, but excluded because intervention is radiotherapy, not a drug-containing intervention. | 待处理 |
| A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder.Acta Neuropsychiatr | PMID 39415650PMC13130322 | 2024-Oct-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Postoperative C5 Palsy after Anterior or Posterior Decompression for Degenerative Cervical Myelopathy: A Subgroup Analysis of the Multicenter, Prospective, Randomized, Phase III, CSM-Protect Clinical Trial.Spine (Phila Pa 1976) | PMID 38616732无 PMCID | 2024-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.J Crohns Colitis | PMID 38700040PMC11479712 | 2024-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of golimumab in rheumatoid arthritis patients at high risk of a poor prognosis: Post hoc analysis of GO-FORTH study using cluster analysis.Mod Rheumatol | PMID 38780239无 PMCID | 2024-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.Cancer | PMID 39031642PMC11851234 | 2024-Oct-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.Clin Infect Dis | PMID 39099085PMC11478588 | 2024-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.Clin Infect Dis | PMID 39099093PMC11478578 | 2024-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.Clin Infect Dis | PMID 39182994PMC11478586 | 2024-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.Cardiovasc Res | PMID 38753448PMC11481169 | 2024-Oct-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial.Med | PMID 39025066无 PMCID | 2024-Oct-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.J Clin Oncol | PMID 38819031PMC11458101 | 2024-Oct-10 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39268857无 PMCID | 2024-Oct-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.Blood Adv | PMID 39024542PMC11465039 | 2024-Oct-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.Blood Adv | PMID 39167766PMC11460446 | 2024-Oct-08 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.BMJ Open | PMID 39384241PMC11474922 | 2024-Oct-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.Lancet | PMID 39284329PMC12208211 | 2024-Oct-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39288779无 PMCID | 2024-Oct-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial.Lancet | PMID 39368841无 PMCID | 2024-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.Oncologist | PMID 38815152PMC11449114 | 2024-Oct-03 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.Vaccine | PMID 38897895无 PMCID | 2024-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.N Engl J Med | PMID 38912654PMC11598664 | 2024-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.Vaccine | PMID 38937182无 PMCID | 2024-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.N Engl J Med | PMID 39046157无 PMCID | 2024-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment.Sci Rep | PMID 39358448PMC11447083 | 2024-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of Antihypertensive Therapy During Pregnancy on Postpartum Blood Pressure Control.Obstet Gynecol | PMID 39265175无 PMCID | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.Rheumatology (Oxford) | PMID 38258434PMC11443035 | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 38552989无 PMCID | 2024-Oct-01 | 0.95 | The report is an original result from a randomized Phase 3 oncology trial in humans with time-to-event endpoints. However, the intervention is radiation therapy alone without a drug-containing component, which is a required criterion for eligibility in this cohort. | 待处理 |
| Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 38631536无 PMCID | 2024-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial.Int J Surg | PMID 38652147PMC11487029 | 2024-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.Haematologica | PMID 38813715PMC11443371 | 2024-Oct-01 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Effect of local prolonged-release incisional doxycycline on surgical site infection prophylaxis in abdominal colorectal surgery: the SHIELD 1 randomized clinical trial.Int J Surg | PMID 38869970PMC11486998 | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.AIDS | PMID 38905488PMC11365754 | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.J Natl Cancer Inst | PMID 38913881PMC11461162 | 2024-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia.Rhinology | PMID 39058315无 PMCID | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.Clin Cancer Res | PMID 39058425PMC11443247 | 2024-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)-Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD).Ann Surg | PMID 39069901PMC11728768 | 2024-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Clin Cancer Res | PMID 39087959PMC11443208 | 2024-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical Trial.JAMA Pediatr | PMID 39102225PMC12549143 | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.JAMA Dermatol | PMID 39141364PMC11325239 | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial.JAMA | PMID 39158894PMC11334013 | 2024-Oct-01 | 0.85 | The trial is a randomized Phase III study in cancer patients, but the intervention is not a cancer-specific drug therapy (it is tranexamic acid for perioperative bleeding reduction), and the primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS, DFS). | 待处理 |
| RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE HARBOR STUDY.Retina | PMID 39287532无 PMCID | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study.Retina | PMID 39287533PMC11398290 | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.J Am Coll Cardiol | PMID 39322323无 PMCID | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD).BMJ Open Ophthalmol | PMID 39353678PMC11448128 | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |